Evidence map›Paper›PMID 23644096›Full record

ArticleExperimental eye research2013

Caffeine eye drops protect against UV-B cataract.

Martin Kronschläger, Stefan Löfgren, Zhaohua Yu, Nooshin Talebizadeh, Shambhu D Varma, Per Söderberg

Open access · greenAbstract read
In one paragraph

Article in Experimental eye research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Caffeine and Vision: Effects on the Eye.Turkish journal of ophthalmology · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Current Trends in the Pharmacotherapy of Cataracts.Pharmaceuticals (Basel, Switzerland) · 2020
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Effect of coffee (caffeine) against human cataract blindness.Clinical ophthalmology (Auckland, N.Z.) · 2016
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Martin KronschlägerGullstrand Lab., Ophthalmology, Dept. of Neuroscience, Uppsala University, Sweden. martin.kronschlager@neuro.uu.se
Stefan Löfgren
Zhaohua Yu
Nooshin Talebizadeh
Shambhu D Varma
Per Söderberg
Uppsala University · SES:t Eriks Ögonsjukhus · SEUniversity of Maryland, Baltimore · US

Funding

OXIDATIVE STRESS ON THE OCULAR LENSR01EY001292 · NEI · UNIVERSITY OF MARYLAND BALTIMORE · PI VARMA, SHAMBHU D · 1986 to 2010
$3.5M
NEI NIH HHS R01 EY001292PHS HHS NEI1292
6 · The paper itself

Abstract

The purpose of this study was to investigate if topically applied caffeine protects against in vivo ultraviolet radiation cataract and if so, to estimate the protection factor. Three experiments were carried out. First, two groups of Sprague-Dawley rats were pre-treated with a single application of either placebo or caffeine eye drops in both eyes. All animals were then unilaterally exposed in vivo to 8 kJ/m(2) UV-B radiation for 15 min. One week later, the lens GSH levels were measured and the degree of cataract was quantified by measurement of in vitro lens light scattering. In the second experiment, placebo and caffeine pre-treated rats were divided in five UV-B radiation dose groups, receiving 0.0, 2.6, 3.7, 4.5 or 5.2 kJ/m(2) UV-B radiation in one eye. Lens light scattering was determined after one week. In the third experiment, placebo and caffeine pre-treated rats were UV-B-exposed and the presence of activated caspase-3 was visualized by immunohistochemistry. There was significantly less UV-B radiation cataract in the caffeine group than in the placebo group (95% confidence interval for mean difference in lens light scattering between the groups = 0.10 ± 0.05 tEDC), and the protection factor for caffeine was 1.23. There was no difference in GSH levels between the placebo- and the caffeine group. There was more caspase-3 staining in UV-B-exposed lenses from the placebo group than in UV-B-exposed lenses from the caffeine group. Topically applied caffeine protects against ultraviolet radiation cataract, reducing lens sensitivity 1.23 times.

Indexed as

Administration, TopicalAnimalsCaffeineCaspase 3CataractCentral Nervous System StimulantsFluorescent Antibody Technique, IndirectGlutathioneLens, CrystallineMaleOphthalmic SolutionsRadiation DosageRadiation Injuries, ExperimentalRatsRats, Sprague-DawleyScattering, RadiationCaffeineCaspase 3Central Nervous System StimulantsGlutathioneOphthalmic Solutionscaffeinecataractprotection factorultraviolet radiation

Identifiers

PMID23644096
PMCPMC3737395
OpenAlexW2082031952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.